Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Anchor Therapeutics

Request full access

Anchor Therapeutics develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain

Cambridge, United StatesFounded 2006Biotech & Life Sciences

About Anchor Therapeutics

Anchor Therapeutics specializes in designing and developing peptide modulators targeting G protein-coupled receptors (GPCRs), which are the largest family of drug targets. The company's proprietary peptides, known as pepducins, modulate GPCR activity through a unique intracellular allosteric mechanism. This innovative approach is well-suited for a wide range of targets, including difficult-to-treat and orphan receptors. Anchor Therapeutics collaborates with pharmaceutical companies to leverage the broad applications of pepducin technology, aiming to create new treatment options for conditions such as regenerative medicine and diabetes. The company operates in the biotechnology sector, serving pharmaceutical firms and research institutions. Its business model revolves around research and development collaborations, licensing agreements, and co-marketing partnerships. Revenue is generated through milestone payments, licensing fees, and royalties from successful drug developments.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2006
Headquarters
Cambridge, United States
Employees
3
Open positions
None listed
Dealroom signal
54.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Aug 2010 $10M $40M HealthCare Ventures · TVM Capital Life Science · Novartis Venture Fund —
SERIES A✓Equity / VC Jan 2009 $19M $76M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Anchor Therapeutics website traffic

Latest recorded traffic for Anchor Therapeutics is 240 monthly website visits, up 100% over the last three months. Anchor Therapeutics's team grew 0% over the past year.

Latest monthly visits240 3-month web change+100% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Anchor Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Anchor Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • HealthCare Ventures
  • Novartis Venture Fund
  • TVM Capital Life Science

Other known investors1 additional known investor

  • Tufts University
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Anchor Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Anchor Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.